

# Zobair M Younossi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2066308/publications.pdf>

Version: 2024-02-01

614  
papers

81,563  
citations

1238

110  
h-index

507

268  
g-index

624  
all docs

624  
docs citations

624  
times ranked

43110  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 90-102.e6.   | 4.4  | 9         |
| 2  | The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 970-977.e1.  | 4.4  | 1         |
| 3  | Association of Previous Gastric Bypass Surgery and Patient Outcomes in Alcohol-Associated Cirrhosis Hospitalizations. <i>Digestive Diseases and Sciences</i> , 2023, 68, 1026-1034.  | 2.3  | 3         |
| 4  | Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience. <i>Clinical Infectious Diseases</i> , 2022, 74, 1063-1069.                          | 5.8  | 57        |
| 5  | Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1354-1361.e7.                         | 4.4  | 29        |
| 6  | A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1456-e1468.   | 4.4  | 49        |
| 7  | Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2050-2058.e12.                                 | 4.4  | 41        |
| 8  | Dietary Risks for Liver Mortality in NAFLD: Global Burden of Disease Data. <i>Hepatology Communications</i> , 2022, 6, 90-100.   | 4.3  | 22        |
| 9  | Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID-19 Infection. <i>Hepatology Communications</i> , 2022, 6, 3062-3072.   | 4.3  | 36        |
| 10 | Liver Transplant Center Size and the Impact on Clinical Outcomes and Resource Utilization. <i>Transplantation</i> , 2022, 106, 988-996.  | 1.0  | 6         |
| 11 | Serum Biomarkers are Associated With Atherosclerotic Cardiovascular Disease Among Patients With Nonalcoholic Fatty Liver Disease Undergoing Elective Angiography. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1149-e1156. | 4.4  | 2         |
| 12 | Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 438-446.                                      | 4.4  | 10        |
| 13 | The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2915-2917.e1.   | 4.4  | 6         |
| 14 | Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.   | 17.8 | 330       |
| 15 | Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2022, 75, 1235-1246.   | 7.3  | 45        |
| 16 | Global burden of NAFLD and chronic liver disease among adolescents and young adults. <i>Hepatology</i> , 2022, 75, 1204-1217.  | 7.3  | 78        |
| 17 | Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C. <i>Annals of Hepatology</i> , 2022, 27, 100556.   | 1.5  | 32        |
| 18 | Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. <i>Journal of Hepatology</i> , 2022, 76, 536-548.  | 3.7  | 66        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2022, 162, 680-688.  | 1.3 | 53        |
| 20 | Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2296-2306.e6. | 4.4 | 35        |
| 21 | Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2022, 117, 453-461.   | 0.4 | 28        |
| 22 | Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. <i>Journal of Hepatology</i> , 2022, 76, 1030-1041.   | 3.7 | 74        |
| 23 | Reply. <i>Hepatology</i> , 2022, 75, 1663-1664.   | 7.3 | 0         |
| 24 | Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis. <i>Endocrine Practice</i> , 2022, 28, 204-213.  | 2.1 | 16        |
| 25 | Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients. <i>Hepatology Communications</i> , 2022, 6, 1506-1515.  | 4.3 | 28        |
| 26 | Outcomes of hospitalized patients with COVID-19 during the course of the pandemic in a fully integrated health system. <i>PLoS ONE</i> , 2022, 17, e0263417.  | 2.5 | 5         |
| 27 | Interrelationship between physical activity and depression in nonalcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2022, 14, 612-622.   | 2.0 | 3         |
| 28 | Health-Related Quality of Life and Health Care Resource Utilization in Patients With Chronic Liver Disease and Primary Liver Cancer in the United States: Analysis of Medical Expenditure Panel Survey. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 272-277.                   | 0.9 | 1         |
| 29 | Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?. <i>Hepatology</i> , 2022, 76, 1423-1437.   | 7.3 | 78        |
| 30 | The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.   | 3.7 | 114       |
| 31 | Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. <i>Hepatology</i> , 2022, 76, 1150-1163.  | 7.3 | 15        |
| 32 | Service line care delivery model for COVID-19 patient-centric care. <i>American Journal of Managed Care</i> , 2022, 28, e80-e87.  | 1.1 | 3         |
| 33 | Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD. <i>Hepatology Communications</i> , 2022, 6, 765-779.   | 4.3 | 26        |
| 34 | Prevalence of High and Moderate Risk Nonalcoholic Fatty Liver Disease Among Adults in the United States, 1999-2016. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2838-2847.e7.   | 4.4 | 38        |
| 35 | American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. <i>Endocrine Practice</i> , 2022, 28, 528-562.   | 2.1 | 323       |
| 36 | Response to Letters to the Editors. <i>Hepatology</i> , 2022, , .   | 7.3 | 2         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes. <i>JHEP Reports</i> , 2022, 4, 100525.  | 4.9 | 23        |
| 38 | From NAFLD to MAFLD: Implications of a Premature Change in Terminology. <i>Hepatology</i> , 2021, 73, 1194-1198.  | 7.3 | 266       |
| 39 | Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 580-589.e5.  | 4.4 | 269       |
| 40 | Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 629-636. | 2.8 | 22        |
| 41 | Physical Activity, Measured Objectively, Is Associated With Lower Mortality in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1240-1247.e5.  | 4.4 | 40        |
| 42 | Health-related quality of life in Cuban patients with chronic liver disease: A real-world experience. <i>Annals of Hepatology</i> , 2021, 22, 100277.   | 1.5 | 12        |
| 43 | The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2021, 160, 1608-1619.e13.   | 1.3 | 60        |
| 44 | Integrating Patient-Reported Outcomes Within Routine Hepatology Care: A Prompt to Action. <i>Hepatology</i> , 2021, 73, 1570-1580.  | 7.3 | 10        |
| 45 | AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review. <i>Gastroenterology</i> , 2021, 160, 912-918.   | 1.3 | 245       |
| 46 | Development and validation of a hepatitis B-specific health-related quality-of-life instrument: CLDQ-HBV. <i>Journal of Viral Hepatitis</i> , 2021, 28, 484-492.  | 2.0 | 13        |
| 47 | NAFLD: Reporting Histologic Findings in Clinical Practice. <i>Hepatology</i> , 2021, 73, 2028-2038.   | 7.3 | 86        |
| 48 | Major Histocompatibility Complex Class I-Related Chain A Alleles and Histology of Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2021, 5, 63-73.  | 4.3 | 4         |
| 49 | Patient-Reported Outcomes in Hepatitis C Infection. , 2021, , 213-219.  |     | 0         |
| 50 | Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2021, 31, 2002-2010.   | 2.1 | 14        |
| 51 | Recent Trends in the Global Burden of Hepatitis B Virus: 2007-2017. <i>Gastroenterology</i> , 2021, 160, 1845-1846.e3.  | 1.3 | 14        |
| 52 | Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease Using Noninvasive Tests From Primary Care and Endocrinology Real-World Practices. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00340.   | 2.5 | 15        |
| 53 | Hospice care utilisation among elderly patients who died with hepatocellular carcinoma in the United States. <i>JHEP Reports</i> , 2021, 3, 100236.   | 4.9 | 7         |
| 54 | Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2021, 5, 1201-1211.   | 4.3 | 16        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. <i>Hepatology</i> , 2021, 74, 133-147.   | 7.3  | 101       |
| 56 | Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100280.   | 4.9  | 8         |
| 57 | Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1299-1300.  | 4.4  | 2         |
| 58 | Defining comprehensive models of care for NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 717-729.  | 17.8 | 72        |
| 59 | Preparing for the NASH Epidemic: A Call to Action. <i>Diabetes Care</i> , 2021, 44, 2162-2172.   | 8.6  | 30        |
| 60 | Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007â€”2016. <i>Hepatology Communications</i> , 2021, 5, 1676-1688.  | 4.3  | 38        |
| 61 | Poor Awareness of Liver Disease Among Adults With NAFLD in the United States. <i>Hepatology Communications</i> , 2021, 5, 1833-1847.   | 4.3  | 54        |
| 62 | The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs. <i>Journal of Hepatology</i> , 2021, 75, S3-S13.  | 3.7  | 51        |
| 63 | The impact of hepatocellular carcinoma diagnosis on patients' healthâ€”related quality of life. <i>Cancer Medicine</i> , 2021, 10, 6273-6281.  | 2.8  | 5         |
| 64 | Association between Activity and Brain-Derived Neurotrophic Factor in Patients with Non-Alcoholic Fatty Liver Disease: A Data-Mining Analysis. <i>Life</i> , 2021, 11, 799.  | 2.4  | 9         |
| 65 | Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. <i>JHEP Reports</i> , 2021, 3, 100305.   | 4.9  | 83        |
| 66 | Preparing for the NASH epidemic: A call to action. <i>Obesity</i> , 2021, 29, 1401-1412.   | 3.0  | 7         |
| 67 | Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 1239-1248. | 0.9  | 7         |
| 68 | Preparing for the NASH Epidemic: A Call to Action. <i>Gastroenterology</i> , 2021, 161, 1030-1042.e8.  | 1.3  | 58        |
| 69 | Preparing for the NASH epidemic: A call to action. <i>Metabolism: Clinical and Experimental</i> , 2021, 122, 154822.   | 3.4  | 25        |
| 70 | Nonalcoholic steatohepatitis: global impact and clinical consequences. <i>Endocrine Connections</i> , 2021, 10, R240-R247.   | 1.9  | 18        |
| 71 | Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease. <i>JAMA Network Open</i> , 2021, 4, e2123923.  | 5.9  | 33        |
| 72 | Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019. <i>Journal of Hepatology</i> , 2021, 75, 795-809.   | 3.7  | 94        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 73 | The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017. <i>Hepatology Communications</i> , 2021, 5, 749-759.  | 4.3  | 25        |
| 74 | Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. <i>American Journal of Gastroenterology</i> , 2021, 116, 254-262. | 0.4  | 65        |
| 75 | Reply to Bailly, et al. <i>Clinical Infectious Diseases</i> , 2021, , .   | 5.8  | 0         |
| 76 | Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported Outcomes. <i>Clinical Infectious Diseases</i> , 2020, 70, 628-632.   | 5.8  | 8         |
| 77 | Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis. <i>Journal of Gastroenterology</i> , 2020, 55, 330-341.  | 5.1  | 20        |
| 78 | Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 468-476.e11.   | 4.4  | 16        |
| 79 | Epidemiology of chronic liver diseases in the USA in the past three decades. <i>Gut</i> , 2020, 69, 564-568.  | 12.1 | 321       |
| 80 | Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients. <i>Digestive Diseases and Sciences</i> , 2020, 65, 416-422.   | 2.3  | 6         |
| 81 | Hypothetical treatment of patients with non-alcoholic steatohepatitis: Potential impact on important clinical outcomes. <i>Liver International</i> , 2020, 40, 308-318.   | 3.9  | 4         |
| 82 | Genecriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. <i>Contemporary Clinical Trials</i> , 2020, 89, 105922.  | 1.8  | 92        |
| 83 | Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , 2020, 40, 260-270.   | 3.9  | 24        |
| 84 | Are Noninvasive Scoring Systems for Persons With Chronic Liver Disease Ready for Prime Time?. <i>Gastroenterology</i> , 2020, 158, 40-42.   | 1.3  | 5         |
| 85 | The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 291-304.  | 3.7  | 37        |
| 86 | Increased cancer rates in patients with chronic hepatitis C. <i>Liver International</i> , 2020, 40, 685-693.  | 3.9  | 22        |
| 87 | Among Medicare Patients With Hepatocellular Carcinoma, Non-alcoholic Fatty Liver Disease is the Most Common Etiology and Cause of Mortality. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 459-467.   | 2.2  | 39        |
| 88 | The Burden of NAFLD Worldwide. , 2020, , 15-24.   |      | 0         |
| 89 | Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities. <i>Hepatology Communications</i> , 2020, 4, 1136-1148.  | 4.3  | 56        |
| 90 | Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality. <i>American Journal of Gastroenterology</i> , 2020, 115, 1496-1504.   | 0.4  | 40        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | The times they are a-changin' (for NAFLD as well). <i>Journal of Hepatology</i> , 2020, 73, 1307-1309.   | 3.7 | 45        |
| 92  | Abnormal cardiac and metabolic measures correlate significantly with lower performance and activity in overweight chronic liver disease. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1915-1923.  | 2.0 | 1         |
| 93  | Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient-Reported Outcomes. <i>Hepatology Communications</i> , 2020, 4, 1637-1650.   | 4.3 | 32        |
| 94  | Editorial: a diabetologist's perspective on the diagnosis and monitoring of NAFLD—Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 712-712.   | 3.7 | 1         |
| 95  | Significant knowledge gap about non-alcoholic fatty liver disease (NAFLD) in real-world practices: a global survey of hepatologists, gastroenterologists, endocrinologists and primary care physicians. <i>Journal of Hepatology</i> , 2020, 73, S440. | 3.7 | 2         |
| 96  | The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007–2017. <i>Hepatology Communications</i> , 2020, 4, 1769-1780.   | 4.3 | 54        |
| 97  | Decline in Annual Mortality of Hepatitis C Virus-Related Hepatocellular Carcinoma in the United States, From 2009 to 2018. <i>Gastroenterology</i> , 2020, 159, 1558-1560.e2.  | 1.3 | 17        |
| 98  | Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong. <i>Hepatology Research</i> , 2020, 50, 1024-1031.   | 3.4 | 38        |
| 99  | Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. <i>Journal of Hepatology</i> , 2020, 73, 26-39.  | 3.7 | 290       |
| 100 | Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 513-526.  | 3.7 | 66        |
| 101 | Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. <i>Hepatology</i> , 2020, 72, 1605-1616.  | 7.3 | 431       |
| 102 | MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.   | 1.3 | 1,840     |
| 103 | Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.. <i>Diabetes Care</i> , 2020, 43, 283-289.   | 8.6 | 115       |
| 104 | Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006–2016. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz509.   | 0.9 | 11        |
| 105 | Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 158, 1611-1625.e12.  | 1.3 | 575       |
| 106 | Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States. <i>Hepatology Communications</i> , 2020, 4, 890-903.   | 4.3 | 53        |
| 107 | Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population. <i>Hepatology International</i> , 2020, 14, 556-566.  | 4.2 | 27        |
| 108 | Gamma glutamyltransferase and risk of dementia in prediabetes and diabetes. <i>Scientific Reports</i> , 2020, 10, 6800.  | 3.3 | 12        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2020, 2, 100171.   | 4.9 | 54        |
| 110 | Epidemiology of Non-alcoholic Fatty Liver Disease in North America. <i>Current Pharmaceutical Design</i> , 2020, 26, 993-997.  | 1.9 | 45        |
| 111 | Management of nonalcoholic fatty liver disease in the Middle East. <i>World Journal of Gastroenterology</i> , 2020, 26, 3528-3541.   | 3.3 | 14        |
| 112 | Outcomes of liver transplantation by insurance types in the United States. <i>American Journal of Managed Care</i> , 2020, 26, e121-e126.  | 1.1 | 17        |
| 113 | Letter: the use of Fibrosisâ€4 score in primary care and diabetology practicesâ€”Occam's razor applied to advanced fibrosis screening. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1761-1761.            | 3.7 | 0         |
| 114 | Viral eradication is required for sustained improvement of patientâ€reported outcomes in patients with hepatitis C. <i>Liver International</i> , 2019, 39, 54-59.  | 3.9 | 27        |
| 115 | Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 748-755.e3.  | 4.4 | 559       |
| 116 | Impact of Nonmalignant Portal Vein Thrombosis in Transplant Recipients With Nonalcoholic Steatohepatitis. <i>Liver Transplantation</i> , 2019, 25, 68-78.  | 2.4 | 25        |
| 117 | Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Use. <i>Hepatology</i> , 2019, 69, 237-244.   | 7.3 | 18        |
| 118 | Changing Trends in Etiologyâ€Based and Ethnicityâ€Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States. <i>Hepatology</i> , 2019, 69, 1064-1074.  | 7.3 | 154       |
| 119 | Prevalence, mortality and healthcare utilization among Medicare beneficiaries with Hepatitis C in Haemodialysis units. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1293-1300.  | 2.0 | 5         |
| 120 | REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. <i>Contemporary Clinical Trials</i> , 2019, 84, 105803. | 1.8 | 105       |
| 121 | Validation of the chronic liver disease questionnaire for non-alcoholic steatohepatitis in patients: impact for the clinic. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 709-710.                                 | 3.0 | 0         |
| 122 | Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> , 2019, 70, 1521-1530.   | 7.3 | 197       |
| 123 | The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019, 71, 793-801.   | 3.7 | 1,253     |
| 124 | Hepatocellular carcinoma and non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2019, 13, 688-694.   | 4.2 | 56        |
| 125 | Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States. <i>Hepatology Communications</i> , 2019, 3, 1459-1471.   | 4.3 | 150       |
| 126 | SAT-269-The sustained deleterious impact of viremia on patient reported outcomes in patients with chronic hepatitis C who donâ€™t achieve sustained virologic response. <i>Journal of Hepatology</i> , 2019, 70, e753.                   | 3.7 | 1         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Relationships among neurotransmitters, cytokines and cognitive performance for individuals with hepatitis C achieving sustained virologic response: A pilot study. <i>Journal of Neuroimmunology</i> , 2019, 335, 577022. | 2.3 | 10        |
| 128 | Sa1612 “ Mortality Related to Non-Alcoholic Fatty Liver Disease is Increasing in the United States Over the Last Decade. <i>Gastroenterology</i> , 2019, 156, S-1253.   | 1.3 | 1         |
| 129 | Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2383-2384.   | 4.4 | 1         |
| 130 | A systematic literature review on the use of platelet transfusions in patients with thrombocytopenia. <i>Hematology</i> , 2019, 24, 679-719.  | 1.5 | 18        |
| 131 | Burden of Primary Biliary Cholangitis Among Inpatient Population in the United States. <i>Hepatology Communications</i> , 2019, 3, 356-364.   | 4.3 | 8         |
| 132 | Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005–2016. <i>Hepatology International</i> , 2019, 13, 205-213.  | 4.2 | 63        |
| 133 | Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. <i>Liver International</i> , 2019, 39, 1837-1844.                                     | 3.9 | 18        |
| 134 | Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2019, 3, 1050-1060.   | 4.3 | 44        |
| 135 | Trends in hospitalizations for chronic liver disease–related liver failure in the United States, 2005–2014. <i>Liver International</i> , 2019, 39, 1661-1671.   | 3.9 | 32        |
| 136 | Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States. <i>BMC Gastroenterology</i> , 2019, 19, 56.  | 2.0 | 65        |
| 137 | Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2093-2100.e3. | 4.4 | 33        |
| 138 | Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2552-2560.e10.                        | 4.4 | 65        |
| 139 | The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. <i>Hepatology</i> , 2019, 70, 1913-1927.   | 7.3 | 226       |
| 140 | Resource Utilization and Outcomes of Medicare Recipients With Chronic Hepatitis B in the United States. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, e341-e347.  | 2.2 | 0         |
| 141 | Disease Burden of Hepatocellular Carcinoma: A Global Perspective. <i>Digestive Diseases and Sciences</i> , 2019, 64, 910-917.   | 2.3 | 223       |
| 142 | Cytokine balance is restored as patient-reported outcomes improve in patients recovering from chronic hepatitis C. <i>Liver International</i> , 2019, 39, 1631-1640.  | 3.9 | 7         |
| 143 | Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality. <i>Clinical Diabetes</i> , 2019, 37, 65-72.  | 2.2 | 77        |
| 144 | Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1625-1633.e1.       | 4.4 | 107       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 145 | Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis. BMC Gastroenterology, 2019, 19, 27. | 2.0  | 15        |
| 146 | Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia. Alimentary Pharmacology and Therapeutics, 2019, 49, 644-653.      | 3.7  | 24        |
| 147 | IDDF2019-ABS-0131...Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials. , 2019, , .                   |      | 0         |
| 148 | Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life. American Journal of Gastroenterology, 2019, 114, 1636-1641.                           | 0.4  | 36        |
| 149 | Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.       | 13.7 | 818       |
| 150 | Analysis of human leukocyte antigen allele polymorphism in patients with non alcoholic fatty liver disease. Medicine (United States), 2019, 98, e16704.  | 1.0  | 7         |
| 151 | A Comprehensive Review of Patient-reported Outcomes in Patients With Chronic Liver Diseases. Journal of Clinical Gastroenterology, 2019, 53, 331-341.  | 2.2  | 27        |
| 152 | The Impact of Obesity and Type 2 Diabetes on Chronic Liver Disease. American Journal of Gastroenterology, 2019, 114, 1714-1715.  | 0.4  | 25        |
| 153 | Implementation of Value-based Medicine (VBM) to Patients With Chronic Hepatitis C (HCV) Infection. Journal of Clinical Gastroenterology, 2019, 53, 262-268.                                      | 2.2  | 3         |
| 154 | Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States. Hepatology, 2019, 69, 564-572.   | 7.3  | 142       |
| 155 | Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology, 2019, 69, 2672-2682.   | 7.3  | 1,203     |
| 156 | Factors Associated With Potential Progressive Course of Primary Biliary Cholangitis. Journal of Clinical Gastroenterology, 2019, 53, 693-698.  | 2.2  | 5         |
| 157 | Long-term Effects of Treatment for Chronic HBV Infection on Patient-Reported Outcomes. Clinical Gastroenterology and Hepatology, 2019, 17, 1641-1642.e1.   | 4.4  | 12        |
| 158 | Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. Transplantation, 2019, 103, 22-27.                                    | 1.0  | 296       |
| 159 | Prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among Asian American adults in the United States. Liver International, 2019, 39, 748-757.                                   | 3.9  | 46        |
| 160 | Nonalcoholic Steatohepatitis Is Becoming a Top Indication for Liver Transplantation Worldwide. Liver Transplantation, 2019, 25, 10-11.   | 2.4  | 19        |
| 161 | Non-alcoholic fatty liver disease " A global public health perspective. Journal of Hepatology, 2019, 70, 531-544.  | 3.7  | 1,345     |
| 162 | Diagnosis and Management of Primary Biliary Cholangitis. American Journal of Gastroenterology, 2019, 114, 48-63.   | 0.4  | 100       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population. <i>Hepatology Communications</i> , 2019, 3, 74-83.   | 4.3 | 38        |
| 164 | Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 342-352.  | 3.9 | 38        |
| 165 | Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 332-341.  | 3.9 | 41        |
| 166 | Nonalcoholic Fatty Liver is Contributing to the Increase in Cases of Liver Disease in US Emergency Departments. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 58-64.  | 2.2 | 3         |
| 167 | Aerobic capacity and exercise performance in nonalcoholic fatty liver disease. <i>Journal of Sports Medicine and Physical Fitness</i> , 2019, 59, 1376-1388.  | 0.7 | 15        |
| 168 | Importance of fatigue and its measurement in chronic liver disease. <i>World Journal of Gastroenterology</i> , 2019, 25, 3669-3683.   | 3.3 | 45        |
| 169 | Impact of hepatitis C virus and insurance coverage on mortality. <i>American Journal of Managed Care</i> , 2019, 25, 61-67.   | 1.1 | 7         |
| 170 | French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations: The Effect on Patient-Reported Outcomes. <i>Value in Health</i> , 2018, 21, 1218-1225.  | 0.3 | 21        |
| 171 | Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study. <i>Quality of Life Research</i> , 2018, 27, 1513-1520. | 3.1 | 30        |
| 172 | Quality of Life in Patients with Cirrhosis—Measurement and Clinical Impact. <i>Current Hepatology Reports</i> , 2018, 17, 15-21.  | 0.9 | 1         |
| 173 | Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. <i>Journal of Viral Hepatitis</i> , 2018, 25, 811-817.   | 2.0 | 24        |
| 174 | Real-world use of elbasvir/grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1511-1522.   | 3.7 | 28        |
| 175 | The Stomach as an Endocrine Organ: Expression of Key Modulatory Genes and Their Contribution to Obesity and Non-alcoholic Fatty Liver Disease (NAFLD). <i>Current Gastroenterology Reports</i> , 2018, 20, 24.  | 2.5 | 4         |
| 176 | Patient-Reported Outcomes for Patients With Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 793-799.   | 4.4 | 14        |
| 177 | Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD). <i>BMJ Open Gastroenterology</i> , 2018, 5, e000198.  | 2.7 | 25        |
| 178 | Reply. <i>Hepatology</i> , 2018, 68, 390-390.   | 7.3 | 0         |
| 179 | Increased Waitlist Mortality and Lower Rate for Liver Transplantation in Hispanic Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 965-973.e2.  | 4.4 | 28        |
| 180 | Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. <i>Liver International</i> , 2018, 38, 1849-1859.  | 3.9 | 72        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 181 | Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection—Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 537-538.                                    | 3.7 | 0         |
| 182 | Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation. <i>Liver Transplantation</i> , 2018, 24, 166-170.   | 2.4 | 52        |
| 183 | Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 567-574.e6.                    | 4.4 | 25        |
| 184 | Hospice care in Medicare patients with primary liver cancer: the impact on resource utilisation and mortality. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 680-688.  | 3.7 | 14        |
| 185 | Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. <i>Clinical Infectious Diseases</i> , 2018, 66, 1742-1750.                                 | 5.8 | 21        |
| 186 | Hepatitis C Virus—Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens. <i>Journal of Infectious Diseases</i> , 2018, 217, 1033-1043. | 4.0 | 24        |
| 187 | The epidemiology of nonalcoholic steatohepatitis. <i>Clinical Liver Disease</i> , 2018, 11, 92-94.   | 2.1 | 64        |
| 188 | Effects of Treatment of Chronic Hepatitis B Virus Infection on Patient-Reported Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1641-1649.e6.  | 4.4 | 29        |
| 189 | Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). <i>Medicine (United States)</i> , 2018, 97, e0214.  | 1.0 | 143       |
| 190 | Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan. <i>Journal of Viral Hepatitis</i> , 2018, 25, 945-951.                                  | 2.0 | 18        |
| 191 | In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered. <i>Liver International</i> , 2018, 38, 258-265.   | 3.9 | 34        |
| 192 | The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018, 67, 328-357.  | 7.3 | 4,738     |
| 193 | Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 123-128.  | 3.7 | 13        |
| 194 | Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. <i>Journal of Viral Hepatitis</i> , 2018, 25, 228-235.  | 2.0 | 12        |
| 195 | Improved Outcomes in HCV Patients Following Liver Transplantation During the Era of Direct-Acting Antiviral Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 452-453.   | 4.4 | 34        |
| 196 | Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2018, 22, 1-10.   | 2.1 | 85        |
| 197 | Health-related Quality of Life in Adolescent Patients With Hepatitis C Genotype 1 Treated With Sofosbuvir and Ledipasvir. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018, 66, 112-116.                                      | 1.8 | 29        |
| 198 | Reply. <i>Hepatology</i> , 2018, 67, 450-451.  | 7.3 | 0         |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 199 | Waist-to-hip circumference ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1082-1091.  | 2.8  | 19        |
| 200 | The efficacy of new antiviral regimens for hepatitis C infection: Evidence from a systematic review. <i>Hepatology</i> , 2018, 67, 1160-1162.  | 7.3  | 3         |
| 201 | Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 11-20.  | 17.8 | 3,487     |
| 202 | Prediction of Health Utility Scores in Patients with Chronic Hepatitis C Using the Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV). <i>Value in Health</i> , 2018, 21, 612-621.   | 0.3  | 8         |
| 203 | Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 259-267.   | 3.7  | 41        |
| 204 | Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin. <i>Journal of Viral Hepatitis</i> , 2018, 25, 354-362.  | 2.0  | 20        |
| 205 | The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. <i>Liver International</i> , 2018, 38, 1179-1187.  | 3.9  | 17        |
| 206 | Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO. <i>Hepatology</i> , 2018, 68, 155-165.  | 7.3  | 22        |
| 207 | Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. <i>Hepatology</i> , 2018, 67, 123-133.  | 7.3  | 1,474     |
| 208 | Epigenome-Wide Association Studies Provide Insight into the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. <i>Annals of Hepatology</i> , 2018, 17, 11-13.  | 1.5  | 4         |
| 209 | Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis. <i>Medicine (United States)</i> , 2018, 97, e11518.   | 1.0  | 57        |
| 210 | Exercise as an intervention for patients with end-stage liver disease. <i>Medicine (United States)</i> , 2018, 97, e12774.   | 1.0  | 14        |
| 211 | A176 SOFOSBUVIR/VELPATASVIR-BASED REGIMENS ARE ASSOCIATED WITH EXCELLENT EFFICACY AND A SIGNIFICANT IMPROVEMENT OF PATIENT-REPORTED OUTCOMES ACROSS PATIENT POPULATIONS: FROM NON-CIRRHOTICS TO COMPENSATED CIRRHOTICS TO DECOMPENSATED CIRRHOTICS. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 307-308. | 0.3  | 0         |
| 212 | Association of Parity in Patients with Chronic Liver Disease. <i>Annals of Hepatology</i> , 2018, 17, 1035-1041.   | 1.5  | 4         |
| 213 | Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481881150.   | 3.2  | 16        |
| 214 | Impact of Chronic Hepatitis B Infection on Patient-Reported Outcomes. <i>Current Hepatology Reports</i> , 2018, 17, 459-465.   | 0.9  | 0         |
| 215 | The comprehensive outcomes of hepatitis C virus infection: A multifaceted chronic disease. <i>Journal of Viral Hepatitis</i> , 2018, 25, 6-14.   | 2.0  | 23        |
| 216 | Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality. <i>Hepatology Communications</i> , 2018, 2, 1227-1234.  | 4.3  | 20        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 217 | Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey. PLoS ONE, 2018, 13, e0204772.   | 2.5 | 19        |
| 218 | The Clinical and Economic Burden of Nonalcoholic Steatohepatitis. Current Hepatology Reports, 2018, 17, 345-349.  | 0.9 | 3         |
| 219 | An exploratory study examining how nano-liquid chromatographyâ€‘mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease. BMC Medicine, 2018, 16, 170. | 5.5 | 8         |
| 220 | Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. Gastroenterology, 2018, 155, 1140-1153.  | 1.3 | 253       |
| 221 | The impact of sustained virologic response on severe fatigue in patients with chronic hepatitis C: The role of HCV viremia and co-morbidities. Journal of Hepatology, 2018, 68, S531.   | 3.7 | 4         |
| 222 | 559 - Factors Associated with Progressive Course of Patients with Primary Biliary Cholangitis in the United States: Data from a Large-Real World Database. Gastroenterology, 2018, 154, S-1097.   | 1.3 | 1         |
| 223 | Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH). PLoS ONE, 2018, 13, e0199294.  | 2.5 | 15        |
| 224 | Response to the letter: Hepatitis C screening in opioid epidemics in the United States and societal perspectives. Liver International, 2018, 38, 1331-1331.   | 3.9 | 0         |
| 225 | Patientâ€‘Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value Proposition. Hepatology, 2018, 68, 2405-2412.  | 7.3 | 39        |
| 226 | Disparities in Access to Direct Acting Antiviral Regimens for Hepatitis C Virus (HCV): The Impact of Race and insurance Status. American Journal of Gastroenterology, 2018, 113, 1285-1286.   | 0.4 | 4         |
| 227 | Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of healthâ€‘related quality of life in East Asian patients with hepatitis C virus infection. Journal of Viral Hepatitis, 2018, 25, 1429-1437.               | 2.0 | 16        |
| 228 | Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016. Journal of Viral Hepatitis, 2018, 25, 1608-1616.  | 2.0 | 13        |
| 229 | The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. Journal of Hepatology, 2018, 69, 1365-1370.   | 3.7 | 51        |
| 230 | Cognitive Performance in Individuals With Non-Alcoholic Fatty Liver Disease and/or Type 2 Diabetes Mellitus. Psychosomatics, 2018, 59, 567-574.   | 2.5 | 33        |
| 231 | Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. , 2018, 68, 349.   |     | 1         |
| 232 | Chronic kidney disease in patients with chronic hepatitis C virus infection. Minerva Gastroenterologica E Dietologica, 2018, 64, 376-382.   | 2.2 | 2         |
| 233 | Disparities in Liver Transplantation Resulting From Variations in Regional Donor Supply and Multiple Listing Practices. Clinical Gastroenterology and Hepatology, 2017, 15, 313-315.  | 4.4 | 12        |
| 234 | Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and metaâ€‘analysis. Hepatology, 2017, 65, 1557-1565.  | 7.3 | 1,294     |



| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 235 | The epidemiologic characteristics, temporal trends, predictors of death, and discharge disposition in patients with a diagnosis of sepsis: A cross-sectional retrospective cohort study. <i>Journal of Critical Care</i> , 2017, 39, 48-55. | 2.2  | 12        |
| 236 | Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017, 66, 1282-1299.   | 3.7  | 73        |
| 237 | A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: <scp>CLDQ</scp>â€<scp>NAFLD</scp>. <i>Liver International</i> , 2017, 37, 1209-1218.                                 | 3.9  | 72        |
| 238 | Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States. <i>Journal of Viral Hepatitis</i> , 2017, 24, 789-796.  | 2.0  | 15        |
| 239 | Hepatitis C virus infection. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17006.  | 30.5 | 354       |
| 240 | Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 25.                                     | 2.4  | 19        |
| 241 | Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States. <i>Hepatology</i> , 2017, 66, 46-56.  | 7.3  | 24        |
| 242 | Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1087-1094.e2.           | 4.4  | 19        |
| 243 | Hepatitis C Infection. <i>Clinics in Liver Disease</i> , 2017, 21, 449-453.   | 2.1  | 26        |
| 244 | Economic Burden of Hepatitis C Infection. <i>Clinics in Liver Disease</i> , 2017, 21, 579-594.  | 2.1  | 54        |
| 245 | Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study. <i>Liver International</i> , 2017, 37, 1796-1804.                    | 3.9  | 30        |
| 246 | Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2174-2181.                                      | 2.3  | 22        |
| 247 | Patient-Reported Outcomes and Fatigue in Patients with Chronic Hepatitis C Infection. <i>Clinics in Liver Disease</i> , 2017, 21, 565-578.  | 2.1  | 32        |
| 248 | Hepatitis C Virus Infection Care Pathwayâ€”A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. <i>Gastroenterology</i> , 2017, 152, 1588-1598.  | 1.3  | 10        |
| 249 | The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?. <i>Liver International</i> , 2017, 37, 662-668.  | 3.9  | 16        |
| 250 | Dermatologic Manifestations of Chronic Hepatitis C Infection. <i>Clinics in Liver Disease</i> , 2017, 21, 555-564.  | 2.1  | 23        |
| 251 | Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study. <i>Journal of Hepatology</i> , 2017, 67, 940-949.   | 3.7  | 85        |
| 252 | Long-Term Outcomes of Nonalcoholic Fatty Liver Disease: From Nonalcoholic Steatohepatitis to Nonalcoholic Steatofibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1144-1147.  | 4.4  | 27        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 253 | Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial). <i>Patient</i> , 2017, 10, 605-614.                                       | 2.7 | 4         |
| 254 | International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2017, 16, 523-541.  | 5.8 | 87        |
| 255 | Demographics, Resource Utilization, and Outcomes of Elderly Patients With Chronic Liver Disease Receiving Hospice Care in the United States. <i>American Journal of Gastroenterology</i> , 2017, 112, 1700-1708.                           | 0.4 | 21        |
| 256 | Preface. <i>Clinics in Liver Disease</i> , 2017, 21, xiii.   | 2.1 | 0         |
| 257 | Should adults with diabetes mellitus be vaccinated against hepatitis B virus? A systematic review of diabetes mellitus and the progression of hepatitis B disease. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2695-2706.     | 3.3 | 21        |
| 258 | Effectiveness of 8 or 12 weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 540-548.                                  | 3.7 | 36        |
| 259 | Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2915-2922.  | 2.3 | 192       |
| 260 | Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2017, 21, 739-753.   | 2.1 | 31        |
| 261 | Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2017, 1, 421-428.   | 4.3 | 101       |
| 262 | Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. <i>Medicine (United States)</i> , 2017, 96, e5904.  | 1.0 | 181       |
| 263 | Superiority of Interferon-Free Regimens for Chronic Hepatitis C. <i>Medicine (United States)</i> , 2017, 96, e5914.  | 1.0 | 42        |
| 264 | Demonstration of two types of fatigue in subjects with chronic liver disease using factor analysis. <i>Quality of Life Research</i> , 2017, 26, 1777-1784.   | 3.1 | 9         |
| 265 | Real-world effectiveness for 12 weeks of ledipasvir+sofosbuvir for genotype 1 hepatitis C: the Trio Health study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 22-27.   | 2.0 | 69        |
| 266 | The impact of hepatitis C virus outside the liver: Evidence from Asia. <i>Liver International</i> , 2017, 37, 159-172.   | 3.9 | 38        |
| 267 | Direct and Indirect Economic Burden of Chronic Liver Disease in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 759-766.e5.   | 4.4 | 110       |
| 268 | Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 421-430.e6. | 4.4 | 72        |
| 269 | Patients With Diabetes and Chronic Liver Disease Are at Increased Risk for Overall Mortality: A Population Study From the United States. <i>Clinical Diabetes</i> , 2017, 35, 79-83.   | 2.2 | 14        |
| 270 | Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 254-260.     | 2.2 | 63        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 271 | Fatigue and Hepatitis C: a focus group study. <i>Qualitative Research in Medicine &amp; Healthcare</i> , 2017, 1, .  | 0.2 | 4         |
| 272 | Pediatric Non-Alcoholic Fatty Liver Disease. <i>Children</i> , 2017, 4, 48.  | 1.5 | 41        |
| 273 | Independent Predictors of Mortality and Resource Utilization in Viral Hepatitis Related Hepatocellular Carcinoma. <i>Annals of Hepatology</i> , 2017, 16, 555-564.   | 1.5 | 18        |
| 274 | The Prevalence of Parkinson Disease Among Patients With Hepatitis C Infection. <i>Annals of Hepatology</i> , 2017, 16, 342-348.  | 1.5 | 9         |
| 275 | Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States. <i>Journal of Clinical and Translational Hepatology</i> , 2017, 5, 16-22.                   | 1.4 | 3         |
| 276 | Rising Rate of Liver Transplantation in the Baby Boomer Generation with Non-alcoholic Steatohepatitis in the United States. <i>Journal of Clinical and Translational Hepatology</i> , 2017, XX, 1-4.                       | 1.4 | 6         |
| 277 | Treating Medicaid patients with hepatitis C: clinical and economic impact. <i>American Journal of Managed Care</i> , 2017, 23, 107-112.  | 1.1 | 21        |
| 278 | Trends in Liver Transplantation in Hepatitis C Virusâ€“Infected Persons, United States. <i>Emerging Infectious Diseases</i> , 2016, 22, 565-567.   | 4.3 | 2         |
| 279 | Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. <i>World Journal of Gastroenterology</i> , 2016, 22, 6318.  | 3.3 | 131       |
| 280 | Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States. <i>Medicine (United States)</i> , 2016, 95, e2482.                               | 1.0 | 13        |
| 281 | Patientâ€“Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferonâ€“and Ribavirinâ€“Free Regimens. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 386-393.                     | 2.6 | 37        |
| 282 | Sofosbuvir and ledipasvir improve patientâ€“reported outcomes in patients coâ€“infected with hepatitis C and human immunodeficiency virus. <i>Journal of Viral Hepatitis</i> , 2016, 23, 857-865.                          | 2.0 | 48        |
| 283 | The impact of ledipasvir/sofosbuvir on patientâ€“reported outcomes in cirrhotic patients with chronic hepatitis C: the <sc>SIRIUS</sc> study. <i>Liver International</i> , 2016, 36, 42-48.                                | 3.9 | 50        |
| 284 | Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (<sc>CH</sc>â€“C) patients: an economic model from five European countries. <i>Journal of Viral Hepatitis</i> , 2016, 23, 217-226. | 2.0 | 45        |
| 285 | Vaccination against hepatitis A and B in patients with chronic liver disease and type 2 diabetes: has anything changed?. <i>Liver International</i> , 2016, 36, 1096-1100.   | 3.9 | 8         |
| 286 | Reply. <i>Hepatology</i> , 2016, 64, 1391-1393.  | 7.3 | 1         |
| 287 | Longâ€“term outcomes of lung transplant recipients with hepatitis C infection: a retrospective study of the U.S. transplant registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 271-278.                 | 3.7 | 23        |
| 288 | Disparate access to treatment regimens in chronic hepatitis <sc>C</sc> patients: data from the <sc>TRIO</sc> network. <i>Journal of Viral Hepatitis</i> , 2016, 23, 447-454.   | 2.0 | 50        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 289 | Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2016, 23, 623-630.   | 2.0 | 35        |
| 290 | Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir. <i>Medicine (United States)</i> , 2016, 95, e2702.   | 1.0 | 34        |
| 291 | Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1 infected treatment-naïve patients. <i>Liver International</i> , 2016, 36, 189-197.  | 3.9 | 23        |
| 292 | An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens. <i>American Journal of Gastroenterology</i> , 2016, 111, 808-816.  | 0.4 | 85        |
| 293 | Nonalcoholic Steatohepatitis and Liver Transplantation. <i>Current Hepatology Reports</i> , 2016, 15, 113-116.  | 0.9 | 1         |
| 294 | Chronic Hepatitis B Is Associated with Higher Inpatient Resource Utilization and Mortality Versus Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2505-2515.  | 2.3 | 12        |
| 295 | Letter: effects of hepatitis C infection on the post-lung transplant mortality – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 768-769.   | 3.7 | 0         |
| 296 | The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH). <i>BMC Medical Genetics</i> , 2016, 17, 63.   | 2.1 | 29        |
| 297 | Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 122-132.      | 8.1 | 63        |
| 298 | Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 659-665.   | 1.4 | 6         |
| 299 | The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes. <i>Journal of Viral Hepatitis</i> , 2016, 23, 53-61.  | 2.0 | 10        |
| 300 | Letter: new treatments for hepatitis C have implications for quality of life in people who inject drug - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 841-842.   | 3.7 | 1         |
| 301 | Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C. <i>Value in Health</i> , 2016, 19, 544-551.   | 0.3 | 36        |
| 302 | Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. <i>Hepatology</i> , 2016, 64, 1893-1899.   | 7.3 | 61        |
| 303 | The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. <i>Hepatology</i> , 2016, 64, 1577-1586.  | 7.3 | 894       |
| 304 | Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. <i>Journal of Hepatology</i> , 2016, 65, S109-S119.  | 3.7 | 52        |
| 305 | International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2016, 15, 1145-1160.   | 5.8 | 87        |
| 306 | Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. <i>Clinical Infectious Diseases</i> , 2016, 63, 1042-1048. | 5.8 | 56        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 307 | Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma. Liver Transplantation, 2016, 22, 1356-1366.                          | 2.4 | 22        |
| 308 | Long-term outcomes of heart transplant recipients with hepatitis C positivity: the data from the U.S. transplant registry. Clinical Transplantation, 2016, 30, 1570-1577.  | 1.6 | 22        |
| 309 | Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease. BMJ Open Gastroenterology, 2016, 3, e000096.   | 2.7 | 43        |
| 310 | Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenterology, 2016, 3, e000106.  | 2.7 | 58        |
| 311 | Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor. BMC Gastroenterology, 2016, 16, 137.   | 2.0 | 24        |
| 312 | The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV). Medicine (United States), 2016, 95, e5066. | 1.0 | 7         |
| 313 | Adherence to treatment of chronic hepatitis C. Medicine (United States), 2016, 95, e4151.  | 1.0 | 68        |
| 314 | Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. Medicine (United States), 2016, 95, e4243.   | 1.0 | 14        |
| 315 | Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States. Medicine (United States), 2016, 95, e5048.  | 1.0 | 32        |
| 316 | Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64, 73-84.  | 7.3 | 7,346     |
| 317 | Identifying patients at risk from nonalcoholic fatty liver-related hepatocellular carcinomas. Hepatic Oncology, 2016, 3, 101-103.  | 4.2 | 3         |
| 318 | Presence of hepatitis C (HCV) infection in Baby Boomers with Medicare is independently associated with mortality and resource utilisation. Alimentary Pharmacology and Therapeutics, 2016, 43, 1060-1068.                            | 3.7 | 16        |
| 319 | 603 Access to Therapy in Era of All DAA Regimens: Real-World Experience From the TRIO Network. Gastroenterology, 2016, 150, S1040.   | 1.3 | 1         |
| 320 | FATIGUE IN JAPANESE PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH LEDIPASVIR AND SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN. Value in Health, 2016, 19, A316-A317.  | 0.3 | 3         |
| 321 | Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study. BMC Gastroenterology, 2016, 16, 45.   | 2.0 | 20        |
| 322 | Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). Health and Quality of Life Outcomes, 2016, 14, 18.  | 2.4 | 109       |
| 323 | Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies. Health and Quality of Life Outcomes, 2016, 14, 49.                              | 2.4 | 2         |
| 324 | Global Epidemiology and Risk Factors for Nonalcoholic Fatty Liver Disease. , 2016, , 21-40.  |     | 2         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 325 | Mental and Emotional Impairment in Patients With Hepatitis C is Related to Lower Work Productivity. <i>Psychosomatics</i> , 2016, 57, 82-88.   | 2.5 | 20        |
| 326 | Epidemiology and natural history of non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1017-1025.   | 3.4 | 339       |
| 327 | Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality. <i>Gastroenterology</i> , 2016, 150, 1778-1785.   | 1.3 | 251       |
| 328 | Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. <i>Gastroenterology</i> , 2016, 150, 1599-1608.   | 1.3 | 315       |
| 329 | Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. <i>Journal of Hepatology</i> , 2016, 65, 33-39.   | 3.7 | 103       |
| 330 | Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. <i>Clinics in Liver Disease</i> , 2016, 20, 205-214.   | 2.1 | 403       |
| 331 | Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 156-164.e3. | 4.4 | 55        |
| 332 | Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 63-71.   | 3.0 | 50        |
| 333 | Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. <i>Journal of Hepatology</i> , 2016, 64, 29-36.                             | 3.7 | 30        |
| 334 | Perception of Effort During Activity in Patients With Chronic Hepatitis C and Nonalcoholic Fatty Liver Disease. <i>PM and R</i> , 2016, 8, 28-34.  | 1.6 | 10        |
| 335 | Underutilization of Living Donor Liver Transplantation in the United States: Bias against MELD 20 and Higher. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 169-174.  | 1.4 | 8         |
| 336 | Treatment strategies for chronic hepatitis C prior to and following liver transplantation. <i>World Journal of Hepatology</i> , 2016, 8, 69.   | 2.0 | 10        |
| 337 | Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. <i>American Journal of Managed Care</i> , 2016, 22, SP205-11.   | 1.1 | 31        |
| 338 | Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C". <i>Journal of Hepatology</i> , 2015, 63, 1534-1535.  | 3.7 | 1         |
| 339 | Overall health-related quality of life in patients with end-stage liver disease. <i>Clinical Liver Disease</i> , 2015, 6, 9-14.  | 2.1 | 24        |
| 340 | The price of shortening anti-hepatitis C virus therapy: Is this truly cost saving?. <i>Clinical Liver Disease</i> , 2015, 6, 126-128.  | 2.1 | 3         |
| 341 | Systematic review: patient-reported outcomes in chronic hepatitis C - the impact of liver disease and new treatment regimens. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 497-520.   | 3.7 | 157       |
| 342 | Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis. <i>BMC Gastroenterology</i> , 2015, 15, 175.  | 2.0 | 27        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 343 | Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. <i>Hepatology</i> , 2015, 62, 1723-1730.  | 7.3 | 633       |
| 344 | The outcomes of adult liver transplants in the United States from 1987 to 2013. <i>Liver International</i> , 2015, 35, 2036-2041.   | 3.9 | 28        |
| 345 | A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2015, 22, 897-905.   | 2.0 | 80        |
| 346 | Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels. <i>Journal of Viral Hepatitis</i> , 2015, 22, 977-982.  | 2.0 | 17        |
| 347 | The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 286-295. | 3.7 | 86        |
| 348 | <sc>HCV</sc> infection is associated with lower survival in simultaneous liver kidney transplant recipients in the United States. <i>Clinical Transplantation</i> , 2015, 29, 920-926.  | 1.6 | 7         |
| 349 | Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. <i>Hepatology</i> , 2015, 61, 1471-1478.   | 7.3 | 44        |
| 350 | Can NASH lipidome provide insight into the pathogenesis of obesity-related non-alcoholic fatty liver disease?. <i>Journal of Hepatology</i> , 2015, 62, 761-762.  | 3.7 | 9         |
| 351 | Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1317-1326.  | 2.4 | 19        |
| 352 | What is the ethical responsibility of a provider when prescribing the new direct-acting antiviral agents to patients with hepatitis C infection?. <i>Clinical Liver Disease</i> , 2015, 6, 117-119.                                       | 2.1 | 8         |
| 353 | Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 544-563.                                       | 3.7 | 108       |
| 354 | Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. <i>Hepatology</i> , 2015, 61, 1798-1808.   | 7.3 | 127       |
| 355 | Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States. <i>Gastroenterology</i> , 2015, 148, 547-555.  | 1.3 | 1,506     |
| 356 | Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced <sc>HCV</sc> genotype 1 patients: <sc>REALIZE</sc> study. <i>Liver International</i> , 2015, 35, 448-454.                 | 3.9 | 6         |
| 357 | Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. <i>Journal of Infectious Diseases</i> , 2015, 212, 367-377.                 | 4.0 | 54        |
| 358 | Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease. <i>Pharmacoeconomics</i> , 2015, 33, 1245-1253.   | 3.3 | 75        |
| 359 | The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 298-312.  | 3.2 | 90        |
| 360 | Resource Utilization and Survival Among Medicare Patients with Advanced Liver Disease. <i>Digestive Diseases and Sciences</i> , 2015, 60, 320-332.  | 2.3 | 10        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 361 | A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Hepatology</i> , 2015, 62, 1204-1206.                          | 3.7 | 52        |
| 362 | Interferon-Free Regimens for Chronic Hepatitis C: Barriers Due to Treatment Candidacy and Insurance Coverage. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3248-3251.  | 2.3 | 25        |
| 363 | Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. <i>Journal of Hepatology</i> , 2015, 63, 337-345. | 3.7 | 148       |
| 364 | Trends in Outpatient Resource Utilizations and Outcomes for Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 222-227.                                     | 2.2 | 43        |
| 365 | Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States. <i>Journal of Viral Hepatitis</i> , 2015, 22, 137-145.                | 2.0 | 29        |
| 366 | Editorial: the association of hepatitis C virus infection and post-liver transplant diabetes – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 489-489.  | 3.7 | 0         |
| 367 | Anti-adipocyte antibody response in patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 900-908.  | 2.8 | 4         |
| 368 | The association of hepatitis C virus infection and post-liver transplant diabetes: data from 17,000 HCV-infected transplant recipients. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 209-217.                   | 3.7 | 17        |
| 369 | Prevalence and determinants of fatty liver in normal-weight and overweight young adults. The Cardiovascular Risk in Young Finns Study. <i>Annals of Medicine</i> , 2015, 47, 40-46.  | 3.8 | 35        |
| 370 | Adipocytokine expression associated with miRNA regulation and diagnosis of NASH in obese patients with NAFLD. <i>Liver International</i> , 2015, 35, 1367-1372.  | 3.9 | 22        |
| 371 | Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment. <i>Journal of Viral Hepatitis</i> , 2015, 22, 8-17.                                 | 2.0 | 15        |
| 372 | Predictors of chronic liver disease in individuals with human immunodeficiency virus infection. <i>Annals of Hepatology</i> , 2014, 13, 60-64.   | 1.5 | 8         |
| 373 | Survey of health status, nutrition and geography of food selection of chronic liver disease patients. <i>Annals of Hepatology</i> , 2014, 13, 533-540.   | 1.5 | 23        |
| 374 | Statin use is not associated with liver related mortality. <i>Annals of Hepatology</i> , 2014, 13, 84-90.  | 1.5 | 13        |
| 375 | Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects. <i>BMC Gastroenterology</i> , 2014, 14, 208.   | 2.0 | 31        |
| 376 | Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study. <i>BMJ Open</i> , 2014, 4, e004318.   | 1.9 | 28        |
| 377 | A single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 2006-2013.               | 2.8 | 65        |
| 378 | Markers of endothelial dysfunction in patients with non-alcoholic fatty liver disease and coronary artery disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1528-1534.                        | 2.8 | 19        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 379 | Editorial: patients' preferences and health utility assessment in those with HCV treated with sofosbuvir - stating the obvious? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1116-1116. | 3.7 | 0         |
| 380 | Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. <i>Hepatology</i> , 2014, 59, 2161-2169.   | 7.3 | 77        |
| 381 | Multiple Factors Predict Physical Performance in People with Chronic Liver Disease. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2014, 93, 470-476.   | 1.4 | 20        |
| 382 | The Portrait of an Adult Liver Transplant Recipient in the United States From 1987 to 2013. <i>JAMA Internal Medicine</i> , 2014, 174, 1407.   | 5.1 | 38        |
| 383 | Obesity and Liver Disease. <i>Clinics in Liver Disease</i> , 2014, 18, xiii-xiv.   | 2.1 | 1         |
| 384 | Reply to: "Cost-effectiveness of upcoming treatments for hepatitis C: We need to get the models right". <i>Journal of Hepatology</i> , 2014, 61, 454-455.  | 3.7 | 0         |
| 385 | Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study. <i>Journal of Hepatology</i> , 2014, 61, 228-234.  | 3.7 | 88        |
| 386 | Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 3-14.                 | 3.7 | 79        |
| 387 | Effects of Sofosbuvir-Based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1349-1359.e13.       | 4.4 | 87        |
| 388 | Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C). <i>Journal of Hepatology</i> , 2014, 60, 741-747.  | 3.7 | 88        |
| 389 | Obesity-Associated Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2014, 18, 19-31.  | 2.1 | 75        |
| 390 | Adipokines in Nonalcoholic Fatty Liver Disease. , 2014, , 249-283.   |     | 2         |
| 391 | Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. <i>Journal of Hepatology</i> , 2014, 60, 530-537.  | 3.7 | 118       |
| 392 | The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, S186-S196.                             | 0.9 | 58        |
| 393 | The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85,000 liver transplant recipients in the US. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 686-694.                    | 3.7 | 72        |
| 394 | Patients' preferences and health utility assessment with SF6D and EQ5D in patients with chronic hepatitis C treated with sofosbuvir regimens. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 676-685.     | 3.7 | 31        |
| 395 | The impact of hepatitis C burden: an evidence-based approach. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 518-531.   | 3.7 | 107       |
| 396 | Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 657-675.        | 3.7 | 62        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 397 | Chronic HCV infection, diabetes and liver-related outcomes. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 520-521.  | 17.8 | 5         |
| 398 | Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study. <i>Lancet</i> , The, 2014, 384, 1756-1765. | 13.7 | 751       |
| 399 | Hepatitis C Virus Infection and Coronary Artery Disease Risk: A Systematic Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1586-1593.  | 2.3  | 50        |
| 400 | Expression of energy metabolism related genes in the gastric tissue of obese individuals with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2014, 14, 72.  | 2.0  | 5         |
| 401 | Monitoring and treatment of inactive chronic hepatitis B: Is it cost-effective?. <i>Hepatology</i> , 2014, 60, 19-21.   | 7.3  | 3         |
| 402 | Host Genetic Variants in Obesity-Related Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2014, 18, 249-267.   | 2.1  | 8         |
| 403 | Adipose Tissue as an Endocrine Organ. <i>Clinics in Liver Disease</i> , 2014, 18, 41-58.  | 2.1  | 148       |
| 404 | Sofosbuvir (Sovaldi) for the treatment of hepatitis C. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 555-566.  | 3.1  | 22        |
| 405 | A New Comorbidity Model for Predicting Mortality in Patients With Cirrhosis: Does It Work?. <i>Gastroenterology</i> , 2014, 146, 19-24.   | 1.3  | 8         |
| 406 | Inpatient Economic and Mortality Assessment for Liver Transplantation. <i>Transplantation</i> , 2014, 97, 98-103.   | 1.0  | 19        |
| 407 | Survey of health status, nutrition and geography of food selection of chronic liver disease patients. <i>Annals of Hepatology</i> , 2014, 13, 533-40.   | 1.5  | 10        |
| 408 | Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS). <i>Journal of Translational Medicine</i> , 2013, 11, 133.   | 4.4  | 59        |
| 409 | Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Digestive Diseases and Sciences</i> , 2013, 58, 3017-3023.   | 2.3  | 236       |
| 410 | Association of Sleep Disorders with Nonalcoholic Fatty Liver Disease (NAFLD): A Population-based Study. <i>Journal of Clinical and Experimental Hepatology</i> , 2013, 3, 181-185.  | 0.9  | 35        |
| 411 | Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 124-133.   | 3.7  | 41        |
| 412 | Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. <i>Journal of Hepatology</i> , 2013, 58, 488-494.   | 3.7  | 19        |
| 413 | Expression of genes for microRNA processing enzymes is altered in advanced non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1410-1415.  | 2.8  | 33        |
| 414 | Comparison of activity level among patients with chronic liver disease. <i>Disability and Rehabilitation</i> , 2013, 35, 907-912.   | 1.8  | 10        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 415 | The impact of chronic hepatitis C on resource utilisation and in-patient mortality for Medicare beneficiaries between 2005 and 2010. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1065-1075.                                 | 3.7  | 31        |
| 416 | Commentary: durability of SVR in chronic hepatitis C patients treated with peginterferon-a2a/ribavirin in combination with a direct-acting anti-viral. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 557-558.                 | 3.7  | 1         |
| 417 | Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 703-709.                      | 3.7  | 63        |
| 418 | In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 352-360. | 3.4  | 141       |
| 419 | Associations of chronic hepatitis C with metabolic and cardiac outcomes. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 647-652.   | 3.7  | 134       |
| 420 | Anthropometric and Clinical Factors Associated with Mortality in Subjects with Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1132-1140.  | 2.3  | 58        |
| 421 | Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. <i>Journal of Hepatology</i> , 2013, 58, 883-889.   | 3.7  | 52        |
| 422 | Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. <i>Hepatology</i> , 2013, 58, 1897-1906.  | 7.3  | 21        |
| 423 | Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. <i>New England Journal of Medicine</i> , 2013, 368, 1878-1887.   | 27.0 | 1,605     |
| 424 | Quality of Life in Cirrhosis. <i>Current Gastroenterology Reports</i> , 2013, 15, 301.  | 2.5  | 67        |
| 425 | Association of Chronic Liver Disease with Depression: A Population-Based Study. <i>Psychosomatics</i> , 2013, 54, 52-59.  | 2.5  | 79        |
| 426 | Interaction of Type 2 diabetes and nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 405-407.  | 3.0  | 9         |
| 427 | Expression of Inflammation-Related Genes Is Altered in Gastric Tissue of Patients with Advanced Stages of NAFLD. <i>Mediators of Inflammation</i> , 2013, 2013, 1-10.   | 3.0  | 5         |
| 428 | Commentary: phlebotomy in non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 1112-1112.   | 3.7  | 2         |
| 429 | Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013, 20, 550-555.   | 2.0  | 34        |
| 430 | The inpatient economic and mortality impact of hepatocellular carcinoma from 2005 to 2009: analysis of the US nationwide inpatient sample. <i>Liver International</i> , 2013, 33, 1281-1286.  | 3.9  | 29        |
| 431 | Mortality associated with alcohol-related liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 596-602.   | 3.7  | 21        |
| 432 | Current management of patients with nonalcoholic fatty liver disease. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 549-558.  | 2.4  | 2         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 433 | Validation of the chronic liver disease questionnaire in Serbian patients. <i>World Journal of Gastroenterology</i> , 2013, 19, 4950.  | 3.3 | 16        |
| 434 | Knowledge-Based Identification of Soluble Biomarkers: Hepatic Fibrosis in NAFLD as an Example. <i>PLoS ONE</i> , 2013, 8, e56009.  | 2.5 | 15        |
| 435 | Predictors of chronic liver disease in individuals with human immunodeficiency virus infection. <i>Annals of Hepatology</i> , 2013, 13, 60-4.  | 1.5 | 2         |
| 436 | Statin use is not associated with liver related mortality. <i>Annals of Hepatology</i> , 2013, 13, 84-90.  | 1.5 | 7         |
| 437 | The Intestinal Microbiota and Liver Disease. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2012, 1, 9-14.  | 0.7 | 46        |
| 438 | Nonalcoholic fatty liver disease and bariatric surgery. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 163-171.  | 3.0 | 27        |
| 439 | Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States. <i>Medicine (United States)</i> , 2012, 91, 319-327.  | 1.0 | 441       |
| 440 | African Americans Are Less Likely to Have Clearance of Hepatitis C Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, e62-e65.   | 2.2 | 15        |
| 441 | Nonalcoholic fatty liver disease (<sc>NAFLD</sc>) is associated with low level of physical activity: a population-based study. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 772-781.  | 3.7 | 197       |
| 442 | The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. <i>Gastroenterology</i> , 2012, 142, 1592-1609.                       | 1.3 | 1,486     |
| 443 | Independent Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in the US Population. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 646-650.   | 4.4 | 297       |
| 444 | Natural history of nonalcoholic fatty liver disease. <i>Clinical Liver Disease</i> , 2012, 1, 112-113.   | 2.1 | 7         |
| 445 | Commentary: physical activity and <sc>NAFLD</sc> â€•cause or effect? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 1098-1099.  | 3.7 | 1         |
| 446 | In-Hospital Mortality and Economic Burden Associated With Hepatic Encephalopathy in the United States From 2005 to 2009. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1034-1041.e1.   | 4.4 | 196       |
| 447 | Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2012, 2, 135-144.  | 0.9 | 70        |
| 448 | Disparities in Activity Level and Nutrition Between Patients With Chronic Hepatitis C and Blood Donors. <i>PM and R</i> , 2012, 4, 436-441.  | 1.6 | 4         |
| 449 | The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>American Journal of Gastroenterology</i> , 2012, 107, 811-826. | 0.4 | 359       |
| 450 | Economic model of a birth cohort screening program for hepatitis C virus. <i>Hepatology</i> , 2012, 55, 1344-1355.   | 7.3 | 102       |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 451 | The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. <i>Hepatology</i> , 2012, 55, 2005-2023. | 7.3  | 2,935     |
| 452 | Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C). <i>Brain and Behavior</i> , 2012, 2, 525-531.  | 2.2  | 12        |
| 453 | Caffeine is protective in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 76-82.   | 3.7  | 123       |
| 454 | Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity. <i>Journal of Viral Hepatitis</i> , 2012, 19, 341-345.  | 2.0  | 43        |
| 455 | Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH-C). <i>Journal of Viral Hepatitis</i> , 2012, 19, 414-422.   | 2.0  | 9         |
| 456 | The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. <i>Journal of Translational Medicine</i> , 2012, 10, 25.  | 4.4  | 22        |
| 457 | Potential mechanisms underlying the associations between liver enzymes and risk for type 2 diabetes. <i>Hepatology</i> , 2012, 55, 968-970.   | 7.3  | 8         |
| 458 | Quality of Life in Hepatic Encephalopathy. , 2012, , 221-231.   |      | 1         |
| 459 | Validation of CLDQ-HCV as a Health Related Quality of Life (HRQL) Instrument for Patients with Chronic Hepatitis C (CH-C). <i>American Journal of Gastroenterology</i> , 2012, 107, S159.   | 0.4  | 2         |
| 460 | A 2012 clinical update for internists in adult nonalcoholic fatty liver disease. <i>Panminerva Medica</i> , 2012, 54, 29-37.  | 0.8  | 12        |
| 461 | Telaprevir for Retreatment of HCV Infection. <i>New England Journal of Medicine</i> , 2011, 364, 2417-2428.   | 27.0 | 1,466     |
| 462 | Protein Pathway Activation Associated with Sustained Virologic Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon (PEG-IFN) and Ribavirin (RBV). <i>Journal of Proteome Research</i> , 2011, 10, 774-779.  | 3.7  | 10        |
| 463 | Oral L-Ornithine-L-Aspartate Improves Health-Related Quality of Life in Cirrhotic Patients with Hepatic Encephalopathy. <i>Clinical Drug Investigation</i> , 2011, 31, 213-220.   | 2.2  | 27        |
| 464 | Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 524-530.e1.  | 4.4  | 933       |
| 465 | Depression in Patients with Nonalcoholic Fatty Liver Disease and Chronic Viral Hepatitis B and C. <i>Psychosomatics</i> , 2011, 52, 127-132.  | 2.5  | 118       |
| 466 | 13 SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY. <i>Journal of Hepatology</i> , 2011, 54, S6-S7.   | 3.7  | 57        |
| 467 | OP12 Similar Svr Rates In Il28b Cc, Ct Or Tt prior relapser, partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the Realize Study. <i>Gut</i> , 2011, 60, A55-A55.  | 12.1 | 0         |
| 468 | Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 801-814.   | 3.7  | 122       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 469 | Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 274-285.                                 | 3.7  | 2,569     |
| 470 | Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 853-861. | 3.7  | 122       |
| 471 | Vietnamese community screening for hepatitis B virus and hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2011, 18, 70-76.   | 2.0  | 30        |
| 472 | A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis. <i>Obesity Surgery</i> , 2011, 21, 431-439.  | 2.1  | 143       |
| 473 | Biomarkers for Non-invasive Diagnosis of Non-alcoholic Steatohepatitis. <i>Obesity Surgery</i> , 2011, 21, 1318-1318.  | 2.1  | 0         |
| 474 | Association of Obestatin, Ghrelin, and Inflammatory Cytokines in Obese Patients with Non-alcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2011, 21, 1750-1757.  | 2.1  | 49        |
| 475 | Non-Invasive markers for hepatic fibrosis. <i>BMC Gastroenterology</i> , 2011, 11, 91.   | 2.0  | 236       |
| 476 | Insurance status and treatment candidacy of hepatitis C patients: Analysis of population-based data from the United States. <i>Hepatology</i> , 2011, 53, 737-745.   | 7.3  | 85        |
| 477 | Reply:. <i>Hepatology</i> , 2011, 53, 1400-1400.   | 7.3  | 0         |
| 478 | Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality. <i>Hepatology</i> , 2011, 53, 1874-1882.   | 7.3  | 525       |
| 479 | Reply:. <i>Hepatology</i> , 2011, 54, 370-371.   | 7.3  | 1         |
| 480 | Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the U.S. population. <i>Hepatology</i> , 2011, 54, 1167-1178.   | 7.3  | 36        |
| 481 | Novel treatment strategies for patients with nonalcoholic fatty liver disease. <i>Clinical Investigation</i> , 2011, 1, 229-239.   | 0.0  | 7         |
| 482 | OPO3 Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results. <i>Gut</i> , 2011, 60, A50-A51.                                       | 12.1 | 1         |
| 483 | Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 479-484.   | 1.5  | 63        |
| 484 | Emerging therapies for hepatitis C virus. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 535-544.   | 2.4  | 22        |
| 485 | Nutritional Assessments of Patients with Non-alcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2010, 20, 154-160.  | 2.1  | 50        |
| 486 | Hepatic Gene Expression of Caucasian and African-American Patients with Obesity-Related Non-Alcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2010, 20, 640-650.   | 2.1  | 48        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 487 | Hepatic Stellate Cell and Myofibroblast-Like Cell Gene Expression in the Explanted Cirrhotic Livers of Patients Undergoing Liver Transplantation. <i>Digestive Diseases and Sciences</i> , 2010, 55, 496-504. | 2.3  | 4         |
| 488 | Validation of endogenous reference genes for qRT-PCR analysis of human visceral adipose samples. <i>BMC Molecular Biology</i> , 2010, 11, 39.   | 3.0  | 94        |
| 489 | A Methodology for Successfully Producing Global Translations of Patient Reported Outcome Measures for Use in Multiple Countries. <i>Value in Health</i> , 2010, 13, 128-131.                                  | 0.3  | 31        |
| 490 | Response to the Letter from Ms. Tamzin Furtado. <i>Value in Health</i> , 2010, 13, 508.   | 0.3  | 1         |
| 491 | Clinical predictors of fibrosis in patients with chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1085-1094.  | 3.7  | 27        |
| 492 | Differential expression of miRNAs in the visceral adipose tissue of patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 487-497.                      | 3.7  | 126       |
| 493 | Functional pathway analysis of genes associated with response to treatment for chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2010, 17, 730-736.  | 2.0  | 8         |
| 494 | Non-Alcoholic Fatty Liver Disease After Liver Transplantation: A Case of Nurture and Nature. <i>American Journal of Gastroenterology</i> , 2010, 105, 621-623.  | 0.4  | 12        |
| 495 | Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. <i>Gut</i> , 2010, 59, 1410-1415.                                  | 12.1 | 239       |
| 496 | Non-Invasive Diagnostic Tests for Non-Alcoholic Fatty Liver Disease. <i>Current Molecular Medicine</i> , 2010, 10, 166-172.   | 1.3  | 27        |
| 497 | Hepatitis C Virus Infection, Age, and Hispanic Ethnicity Increase Mortality From Liver Cancer in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 718-723.                       | 4.4  | 35        |
| 498 | Manifestations of Chronic Hepatitis C Virus Infection Beyond the Liver. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 1017-1029.   | 4.4  | 147       |
| 499 | Phosphoproteomic Biomarkers Predicting Histologic Nonalcoholic Steatohepatitis and Fibrosis. <i>Journal of Proteome Research</i> , 2010, 9, 3218-3224.  | 3.7  | 21        |
| 500 | Review: Treatment options for nonalcoholic fatty liver disease. <i>Therapeutic Advances in Gastroenterology</i> , 2010, 3, 121-137.   | 3.2  | 119       |
| 501 | Hepatitis C and metabolic syndrome. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 209-215.  | 2.4  | 0         |
| 502 | Markers of Insulin Resistance during HVC Treatment: A Relationship to Sustained Virologic Response. <i>FASEB Journal</i> , 2010, 24, 659.4.   | 0.5  | 0         |
| 503 | Treatment regimens for non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2009, 8, S51-S59.   | 1.5  | 42        |
| 504 | Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin. <i>Hepatology</i> , 2009, 49, 763-774.  | 7.3  | 40        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 505 | Predictors of health-related quality of life in patients with chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 469-476.   | 3.7 | 140       |
| 506 | Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. <i>Liver International</i> , 2009, 29, 3-12.                             | 3.9 | 51        |
| 507 | Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C. <i>Liver International</i> , 2009, 29, 1403-1412.         | 3.9 | 15        |
| 508 | Expression of Cytokine Signaling Genes in Morbidly Obese Patients with Non-Alcoholic Steatohepatitis and Hepatic Fibrosis. <i>Obesity Surgery</i> , 2009, 19, 617-624.                                      | 2.1 | 44        |
| 509 | Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 234-238.  | 4.4 | 643       |
| 510 | Independent Predictors of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1224-1229.e2.  | 4.4 | 270       |
| 511 | Nonalcoholic Fatty Liver Disease: A Practical Approach to Evaluation and Management. <i>Clinics in Liver Disease</i> , 2009, 13, 249-266.   | 2.1 | 55        |
| 512 | Monoclonal and Polyclonal Antibodies Against the HCV Envelope Proteins. <i>Clinics in Liver Disease</i> , 2009, 13, 477-486.  | 2.1 | 6         |
| 513 | Adipokines and cytokines in non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 412-421.   | 3.7 | 364       |
| 514 | The factorial structure of the Chronic Liver Disease Questionnaire (CLDQ). <i>Quality of Life Research</i> , 2008, 17, 575-584.   | 3.1 | 47        |
| 515 | A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH). <i>Obesity Surgery</i> , 2008, 18, 1430-1437.   | 2.1 | 255       |
| 516 | Metabolic Syndrome after Laparoscopic Bariatric Surgery. <i>Obesity Surgery</i> , 2008, 18, 1278-1286.  | 2.1 | 34        |
| 517 | Reply to the Letter to the Editor: "A Biomarker Biopsy for the Diagnosis of NASH: Promises from CK-18 Fragments" by Yusuf Yilmaz, Engin Ulukaya, Enver Dolar. <i>Obesity Surgery</i> , 2008, 18, 1509-1510. | 2.1 | 2         |
| 518 | Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index. <i>Liver Transplantation</i> , 2008, 14, 321-326.   | 2.4 | 59        |
| 519 | Long-term improvement in health-related quality of life after orthotopic liver transplantation. <i>Liver Transplantation</i> , 2008, 14, 1404-1405.   | 2.4 | 7         |
| 520 | The future is around the corner: Noninvasive diagnosis of progressive nonalcoholic steatohepatitis. <i>Hepatology</i> , 2008, 47, 373-375.  | 7.3 | 37        |
| 521 | Reply:. <i>Liver International</i> , 2008, 28, 286-287.   | 3.9 | 0         |
| 522 | Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 2-12.                                | 3.7 | 146       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 523 | A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. <i>Journal of Viral Hepatitis</i> , 2008, 15, 370-378.                   | 2.0 | 33        |
| 524 | Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study. <i>American Journal of Gastroenterology</i> , 2008, 103, 2263-2271.  | 0.4 | 294       |
| 525 | Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2008, 49, 608-612.  | 3.7 | 567       |
| 526 | Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 207-215.   | 3.0 | 21        |
| 527 | Effects of Weight Loss on Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2008, 28, 427-433.  | 3.6 | 63        |
| 528 | Novel Technologies in Studying Chronic Liver Disease. , 2008, , 256-276.   |     | 0         |
| 529 | Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome. <i>Cleveland Clinic Journal of Medicine</i> , 2008, 75, 721-728.  | 1.3 | 275       |
| 530 | Evaluation and management of obesity-related nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2007, 4, 432-441.   | 1.7 | 90        |
| 531 | Anger Experiences Among Hepatitis C Patients: Relationship to Depressive Symptoms and Health-Related Quality of Life. <i>Psychosomatics</i> , 2007, 48, 223-229.   | 2.5 | 36        |
| 532 | Epidemiology and Natural History of NAFLD and NASH. <i>Clinics in Liver Disease</i> , 2007, 11, 1-16.  | 2.1 | 388       |
| 533 | Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease. <i>Expert Review of Molecular Diagnostics</i> , 2007, 7, 195-205.                                       | 3.1 | 14        |
| 534 | The Role of Genomics and Proteomics: Technologies in Studying Non-alcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2007, 11, 209-220.  | 2.1 | 28        |
| 535 | Pathologic Assessment of Non-alcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2007, 11, 17-23.   | 2.1 | 61        |
| 536 | The effects of HCV infection and management on health-related quality of life. <i>Hepatology</i> , 2007, 45, 806-816.  | 7.3 | 162       |
| 537 | A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. <i>Hepatology</i> , 2007, 46, 166-172. | 7.3 | 48        |
| 538 | Development and validation of a disease-targeted quality of life instrument in chronic hepatitis B: The hepatitis B quality of life instrument, version 1.0. <i>Hepatology</i> , 2007, 46, 113-121.                        | 7.3 | 65        |
| 539 | Reply:. <i>Hepatology</i> , 2007, 46, 1306-1307.   | 7.3 | 0         |
| 540 | Health-related quality of life in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 815-820.  | 3.7 | 98        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 541 | Impact of non-alcoholic fatty liver disease on chronic hepatitis B. <i>Liver International</i> , 2007, 27, 607-611.   | 3.9 | 96        |
| 542 | Health-related quality of life in patients with chronic hepatitis B. <i>Liver International</i> , 2007, 27, 1119-1125.  | 3.9 | 69        |
| 543 | Fatigue and Health-Related Quality of Life (HRQL) in Chronic Hepatitis C Virus Infection. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2531-2539.   | 2.3 | 139       |
| 544 | Gene Expression Patterns in Hepatic Tissue and Visceral Adipose Tissue of Patients with Non-Alcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2007, 17, 1111-1118.  | 2.1 | 50        |
| 545 | Adipokines in Non-Alcoholic Fatty Liver Disease. , 2007, , 291-305.   |     | 4         |
| 546 | Depression, anemia and health-related quality of life in chronic hepatitis C. <i>Journal of Hepatology</i> , 2006, 44, 491-498.   | 3.7 | 124       |
| 547 | Gene Expression of Leptin, Resistin, and Adiponectin in the White Adipose Tissue of Obese Patients with Non-Alcoholic Fatty Liver Disease and Insulin Resistance. <i>Obesity Surgery</i> , 2006, 16, 1118-1125. | 2.1 | 98        |
| 548 | Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study. <i>Liver Transplantation</i> , 2006, 12, 1381-1389.                                | 2.4 | 110       |
| 549 | Non-alcoholic fatty liver disease and hepatitis C infection. <i>Minerva Gastroenterologica E Dietologica</i> , 2006, 52, 135-43.  | 2.2 | 36        |
| 550 | The metabolic syndrome and nonalcoholic fatty liver disease. <i>Panminerva Medica</i> , 2006, 48, 41-8.   | 0.8 | 17        |
| 551 | The Use of Growth Factors to Manage the Hematologic Side Effects of PEG-Interferon Alfa and Ribavirin. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, S9-S13.  | 2.2 | 54        |
| 552 | High Rates of Uninsured Among HCV-Positive Individuals. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, 826-830.  | 2.2 | 29        |
| 553 | Impact of Adherence on the Outcome of Antiviral Therapy for Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, S23-S27.   | 2.2 | 45        |
| 554 | Predictors of Nonalcoholic Steatohepatitis and Advanced Fibrosis in Morbidly Obese Patients. <i>Obesity Surgery</i> , 2005, 15, 310-315.  | 2.1 | 276       |
| 555 | Obesity-related Differential Gene Expression in the Visceral Adipose Tissue. <i>Obesity Surgery</i> , 2005, 15, 758-765.  | 2.1 | 67        |
| 556 | Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. <i>Liver International</i> , 2005, 25, 760-771.   | 3.9 | 100       |
| 557 | Microarray technology in the study of obesity and non-alcoholic fatty liver disease. <i>Liver International</i> , 2005, 25, 1091-1096.  | 3.9 | 15        |
| 558 | Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. <i>Hepatology</i> , 2005, 41, 790-800.  | 7.3 | 329       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 559 | A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2005, 42, 665-674.  | 7.3 | 209       |
| 560 | MELD fails to measure quality of life in liver transplant candidates. <i>Liver Transplantation</i> , 2005, 11, 218-223.  | 2.4 | 113       |
| 561 | Pegylated Interferon $\alpha$ -2b, Ribavirin and Amantadine for Chronic Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2005, 50, 970-975.                             | 2.3 | 13        |
| 562 | Approach to the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2005, 9, 617-634.   | 2.1 | 28        |
| 563 | Health-related quality of life (HRQL) in chronic liver disease. <i>Digestive and Liver Disease</i> , 2005, 37, 819-820.  | 0.9 | 24        |
| 564 | Interactions between non-alcoholic fatty liver disease and hepatitis C viral infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, S253-S257. | 2.8 | 3         |
| 565 | Nonalcoholic steatohepatitis. <i>Current Treatment Options in Gastroenterology</i> , 2004, 7, 423-430.   | 0.8 | 2         |
| 566 | Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. <i>Hepatology</i> , 2004, 40, 1450-1458.                                | 7.3 | 136       |
| 567 | Nonalcoholic fatty liver disease in patients with type 2 diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 262-265.                                       | 4.4 | 378       |
| 568 | Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. <i>Human Pathology</i> , 2004, 35, 196-199.  | 2.0 | 139       |
| 569 | Obesity and Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2004, 38, 705-709.                                       | 2.2 | 101       |
| 570 | Nonalcoholic fatty liver disease and the epidemic of obesity.. <i>Cleveland Clinic Journal of Medicine</i> , 2004, 71, 657-664.  | 1.3 | 32        |
| 571 | Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. <i>Hepatology</i> , 2003, 38, 75-85.          | 7.3 | 531       |
| 572 | Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. <i>American Journal of Gastroenterology</i> , 2003, 98, 2060-2063.            | 0.4 | 165       |
| 573 | Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis?. <i>Gastroenterology</i> , 2002, 123, 375-378.                                      | 1.3 | 36        |
| 574 | The utility of radiological imaging in nonalcoholic fatty liver disease. <i>Gastroenterology</i> , 2002, 123, 745-750.   | 1.3 | 1,749     |
| 575 | The impact of liver disease on health-related quality of life: A review of the literature. <i>Current Gastroenterology Reports</i> , 2002, 4, 79-83.                         | 2.5 | 42        |
| 576 | Nonalcoholic fatty liver disease: An agenda for clinical research. <i>Hepatology</i> , 2002, 35, 746-752.  | 7.3 | 216       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 577 | Chronic liver disease and health-related quality of life. <i>Gastroenterology</i> , 2001, 120, 305-307.   | 1.3 | 46        |
| 578 | Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. <i>American Journal of Medicine</i> , 2001, 111, 614-621.                   | 1.5 | 68        |
| 579 | Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. <i>Liver</i> , 2001, 21, 266-271.  | 0.1 | 137       |
| 580 | The role of liver biopsy in chronic hepatitis C. <i>Hepatology</i> , 2001, 33, 196-200.   | 7.3 | 208       |
| 581 | Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. <i>Liver Transplantation</i> , 2001, 7, 797-801.  | 2.4 | 236       |
| 582 | Health-related quality of life in chronic liver disease: the impact of type and severity of disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 2199-2205. | 0.4 | 281       |
| 583 | Assessment of Utilities and Health-Related Quality of Life in Patients With Chronic Liver Disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 579-583.     | 0.4 | 133       |
| 584 | Clinical Features and Natural History of Nonalcoholic Steatosis Syndromes. <i>Seminars in Liver Disease</i> , 2001, 21, 017-026.  | 3.6 | 526       |
| 585 | A pharmaco-economic appraisal of therapies for hepatitis B and C. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 205-211.  | 1.8 | 1         |
| 586 | Hepatitis C, interferon alfa, and depression. <i>Hepatology</i> , 2000, 31, 1207-1211.  | 7.3 | 198       |
| 587 | Impact of liver transplantation on health-related quality of life. <i>Liver Transplantation</i> , 2000, 6, 779-783.   | 2.4 | 92        |
| 588 | Cholestatic Liver Diseases and Health-Related Quality of Life. <i>American Journal of Gastroenterology</i> , 2000, 95, 497-502.   | 0.4 | 137       |
| 589 | Immunogenicity of Hepatitis A Vaccine in Decompensated Liver Disease. <i>American Journal of Gastroenterology</i> , 1999, 94, 1601-1604.                                | 0.4 | 91        |
| 590 | Nonalcoholic fatty liver disease. <i>Current Gastroenterology Reports</i> , 1999, 1, 57-62.   | 2.5 | 29        |
| 591 | Hepatic iron and nonalcoholic fatty liver disease. <i>Hepatology</i> , 1999, 30, 847-850.   | 7.3 | 212       |
| 592 | Evidence-based medicine: A method for solving clinical problems in hepatology. <i>Hepatology</i> , 1999, 30, 829-832.   | 7.3 | 13        |
| 593 | Cost effectiveness of interferon $\gamma$ 2b combined with ribavirin for the treatment of chronic hepatitis C. <i>Hepatology</i> , 1999, 30, 1318-1324.                 | 7.3 | 158       |
| 594 | Outcome of De Novo hepatitis C virus infection in heart transplant recipients. <i>Hepatology</i> , 1999, 30, 1293-1298.   | 7.3 | 79        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 595 | Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut, 1999, 45, 295-300.   | 12.1 | 529       |
| 596 | Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology, 1999, 116, 1413-1419.   | 1.3  | 3,005     |
| 597 | CHRONIC VIRAL HEPATITIS IN RENAL TRANSPLANT RECIPIENTS WITH ALLOGRAFTS FUNCTIONING FOR MORE THAN 20 YEARS <sup>1,2</sup> . Transplantation, 1999, 67, 272-275.  | 1.0  | 64        |
| 598 | Agreement in Pathologic Interpretation of Liver Biopsy Specimens in Posttransplant Hepatitis C Infection. Archives of Pathology and Laboratory Medicine, 1999, 123, 143-145.  | 2.5  | 13        |
| 599 | The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. Seminars in Liver Disease, 1999, 19 Suppl 1, 95-102. | 3.6  | 10        |
| 600 | Selective Digestive Decontamination and its Use in Patients with Liver Disease. Disease Management and Health Outcomes, 1998, 4, 17-26.   | 0.4  | 2         |
| 601 | Evaluating asymptomatic patients with mildly elevated liver enzymes. Cleveland Clinic Journal of Medicine, 1998, 65, 150-158.   | 1.3  | 4         |
| 602 | Hepatitis C update: Implications of the blood transfusion "lookback". Cleveland Clinic Journal of Medicine, 1998, 65, 412-422.  | 1.3  | 3         |
| 603 | Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Modern Pathology, 1998, 11, 560-5.   | 5.5  | 209       |
| 604 | Chronic hepatitis C: a clinical overview. Cleveland Clinic Journal of Medicine, 1997, 64, 259-268.  | 1.3  | 9         |
| 605 | Alpha-1 Antitrypsin Deficiency and the Liver. , 0 , 140-154.  |      | 0         |
| 606 | Acute Viral Hepatitis. , 0 , 1-25.  |      | 0         |
| 607 | Autoimmune Liver Disease. , 0 , 155-173.  |      | 0         |
| 608 | Benign and Malignant Tumors of the Liver. , 0 , 195-214.  |      | 0         |
| 609 | Genetic Hemochromatosis and Iron Overload. , 0 , 117-130.   |      | 0         |
| 610 | Drug-Induced Liver Disease (DILI). , 0 , 174-194.   |      | 0         |
| 611 | Complications of Cirrhosis. , 0 , 215-234.  |      | 1         |
| 612 | Chronic Hepatitis C. , 0 , 39-60.   |      | 1         |

| #   | ARTICLE                                  | IF | CITATIONS |
|-----|--|----|-----------|
| 613 | HIV and Viral Hepatitis. , 0, , 61-76.   |    | 1         |
| 614 | Chronic Hepatitis B and D. , 0, , 26-38. |    | 4         |